{
    "nct_id": "NCT06667141",
    "official_title": "ACR-2316-101: Phase 1 Study of ACR-2316 in Subjects With Advanced Solid Tumors",
    "inclusion_criteria": "1. Signed written informed consent.\n2. Histologically or cytologically proven metastatic, recurrent or locally advanced selected solid tumors.\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 at trial entry and an estimated life expectancy of at least 3 months.\n4. Disease must be measurable with at least 1 unidimensional measurable lesion by RECIST v1.1.\n5. Adequate organ functions.\n6. Must have progressed after prior line of treatment.\n\nExclusion Criteria (all participants):\n\n1. Participants with known symptomatic brain metastases.\n2. Participant had systemic therapy or radiation therapy within 2 weeks prior to the first dose of study drug.\n3. Women who are pregnant or lactating.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}